- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01832116
89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients (MMOT)
October 27, 2014 updated by: Prof.dr. E.G.E. de Vries, University Medical Center Groningen
89Zr-MMOT0530A PET Imaging in Patients With Unresectable Pancreatic or Platinum-resistant Ovarian Cancer Before Treatment With DMOT4039A. A Separate Study to the Phase I Study Protocol DMO4993g
The purpose of this multicenter imaging sub study is to evaluate the biodistribution and organ pharmacokinetics of 89Zr-MMOT0530A in patients with unresectable pancreatic or platinum-resistant ovarian cancer.
MMOT0530A is a monoclonal antibody that targets an antigen overexpressed in pancreatic and ovarian cancer.
Subsequent to imaging with 89Zr-MMOT0530A, patients will be treated with DMOT4039A in the DMO4993g protocol (clinicaltrials.gov
identifier NCT01469793) after this study.
DMOT4039A is an antibody-drug conjugate composed of the monoclonal antibody MMOT0530A and the mitotic agent monomethyl auristatin (MMAE).
By imaging patients with the monoclonal antibody MMOT0530A before treatment, the correlation between tumor uptake of 89Zr-MMOT0530A and response to DMOT4039A therapy will be assessed.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A challenge in current drug development using molecular targeted therapies is the high level of heterogeneity that is present in specific tumor types.
The ability to safely and accurately predict the presence or absence of the target is essential for the therapeutic effect of the newly developed drugs.
DMOT0439A is one of those novel designed molecular targeted drugs; an antibody-drug conjugate composed of the monoclonal antibody MMOT0530A and the mitotic agent monomethyl auristatin (MMAE).
In the DMO4993g protocol (clinicaltrials.gov
identifier NCT01469793), the safety and efficacy of DMOT4039A is assessed in patients with unresectable pancreatic or platinum-resistant ovarian cancer.
By performing a 89Zr-MMOT0530A PET scan prior to treatment with DMOT4039A, the uptake of the tracer in the primary and metastatic tumor lesions can be evaluated.
This is likely to provide important information about target expression, whole body drug distribution and the correlation between tumor uptake and response to therapy.
Ultimately the use of a 89Zr- MMOT0530A PET as a complimentary tool for patient selection and risk stratification can be evaluated.
In part A of this study, the optimal tracer dose of 89Zr- MMOT0530A and schedule for PET imaging will be determined.
In part B patients will have PET imaging before treatment in the DMO4993g study on the dose and time points as assessed in part A.
Study Type
Interventional
Enrollment (Actual)
11
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Amsterdam, Netherlands, 1081HV
- VU Medical Center
-
Groningen, Netherlands, 9713GZ
- University Medical Center Groningen
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Histologically documented, incurable, locally advanced or metastatic disease for which no standard therapy exists, consisting of one of the following: Unresectable pancreatic ductal adenocarcinoma or platinum-resistant ovarian cancer
- Measureable disease, defined as at least one bi-dimensionally measurable non-lymph node lesion >/= 1 cm in long-axis diameter on spiral CT scan or at least one bi-dimensionally measurable lymph node measuring >/= 1.5 cm in short-axis diameter on spiral CT scan
- Adequate hematological, renal and liver function
Exclusion criteria:
- Treatment with anti-tumor therapy, including chemotherapy, biologic, experimental or hormonal therapy, within 4 weeks prior to Day 1
- Known active infection
- Current Grade >/= 2 toxicity (except for alopecia, anorexia and fatigue) from prior therapy or Grade >/= 2 neuropathy
- Untreated or active cerebral nervous system (CNS) metastases
- Pregnant or breastfeeding women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tracerinjection
Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
|
Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The in vivo biodistribution measured in SUV values and organ pharmacokinetics (PK) of 89Zr-MMOT0530A
Time Frame: Approximately 1 year
|
|
Approximately 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The 89Zr-MMOT0530A tumor uptake measured in SUV related to the response to DMOT4039A therapy according to RECISt 1.1 criteria
Time Frame: Approximately 1 year
|
The correlation between the 89Zr-MMOT0530A tumor uptake and response to therapy by performing an 89Zr-MMOT0530A PET scan before DMOT4039A therapy, related to CT/MRI response according to RECIST 1.1 criteria.
|
Approximately 1 year
|
Number of patients with adverse events after 89Zr-MMOT0530A injection as a measure of safety and tolerability
Time Frame: Approximately 1 year
|
Safety will be assessed by evaluation of incidence of adverse events.
|
Approximately 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Elisabeth G. de Vries, MD PhD, University Medical Center Groningen
- Principal Investigator: Henk M Verheul, MD PhD, Amsterdam UMC, location VUmc
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2013
Primary Completion (Actual)
May 1, 2014
Study Completion (Actual)
May 1, 2014
Study Registration Dates
First Submitted
April 2, 2013
First Submitted That Met QC Criteria
April 10, 2013
First Posted (Estimate)
April 15, 2013
Study Record Updates
Last Update Posted (Estimate)
October 28, 2014
Last Update Submitted That Met QC Criteria
October 27, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Gastrointestinal Diseases
- Digestive System Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Carcinoma, Ovarian Epithelial
- Pancreatic Diseases
- Ovarian Diseases
- Adnexal Diseases
Other Study ID Numbers
- MMOT imaging
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Digestive System Diseases
-
Suzhou Immunofoco Biotechnology Co., LtdRecruitingAdvanced Digestive System TumorChina
-
Zhejiang Doer Biologics Co., Ltd.RecruitingMalignant Neoplasm of Digestive SystemChina
-
Changhai HospitalShanghai Ultra-T Immune Therapeutics Co. LTDNot yet recruiting
-
The First Affiliated Hospital with Nanjing Medical...Active, not recruitingDigestive System CancerChina
-
Peking University Cancer Hospital & InstituteRecruitingDigestive System CancersChina
-
Mahidol UniversityCompletedDigestive System CancerThailand
-
Innovative Cellular Therapeutics Co., Ltd.Anhui Provincial Cancer HospitalNot yet recruiting
-
University Hospital FreiburgCompletedDigestive System Diseases [C06] | Digestive System Neoplasms [C04.588.274]Germany
-
Peking UniversityRecruitingAdvanced Malignant Solid Tumor of Digestive SystemChina
-
Amway CorpCitruslabsCompletedDigestive System DiseaseUnited States
Clinical Trials on 89Zr-MMOT0530A
-
Telix International Pty LtdCompletedClear Cell Renal Cell CarcinomaUnited Kingdom, United States, Australia, Turkey, Netherlands, Belgium, Canada, France
-
Telix International Pty LtdCompletedCarcinoma, Renal Cell | Clear Cell Renal Cell CarcinomaJapan
-
Telix International Pty LtdGrand Pharmaceutical (China) Co., Ltd.CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Cancer | Suspected Recurrent Renal Clear Cell CarcinomaChina
-
Affiliated Hospital of Jiangnan UniversityRecruiting
-
Wuxi No. 4 People's HospitalNot yet recruitingSolid Tumor, AdultChina
-
South Metropolitan Health ServiceTelix Pharmaceuticals (Innovations) Pty LimitedCompletedUrothelial CarcinomaAustralia
-
Wuxi No. 4 People's HospitalUnknownSolid Tumor, AdultChina
-
Radboud University Medical CenterABX CRO; Telix International Pty LtdCompleted
-
Memorial Sloan Kettering Cancer CenterGenentech, Inc.Completed
-
Telix International Pty LtdRecruitingSoft Tissue Sarcoma | Cervical Cancer | Nasopharyngeal Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Glioblastoma Multiforme | Non Small Cell Lung Cancer | Cholangiocarcinoma | Epithelial Ovarian Cancer | Head and Neck Squamous Cell Carcinoma and other conditionsUnited States